Hans-georg Wirsching

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Loss of MSH6 or MSH2 sensitizes progressive glioblastoma to radiotherapy.

Journal: The Journal of clinical investigation

Published: August 25, 2026

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

Journal: Neuro-oncology advances

Published: March 17, 2026

Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial.

Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial.

Journal: Neuro-oncology

Published: December 04, 2025

Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.

Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes.

Journal: Neuro-oncology

Published: April 18, 2025

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.

Journal: Neuro-oncology

Published: November 22, 2024

A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.

A microenvironment-determined risk continuum refines subtyping in meningioma and reveals determinants of machine learning-based tumor classification.

Journal: Nature genetics

Published: October 30, 2024

Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.

Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.

Journal: Neuro-oncology practice

Published: March 18, 2024

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

Journal: BMC cancer

Published: December 09, 2023

Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype.

Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype.

Journal: Genes & development

Published: November 10, 2023

A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up.

A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up.

Journal: Frontiers in oncology

Published: August 18, 2023

Immunotherapy for Meningiomas.

Immunotherapy for Meningiomas.

Journal: Advances in experimental medicine and biology

Published: July 11, 2023

Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.

Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.

Journal: Acta neuropathologica

Published: May 23, 2023

Showing 1-12 of 54

Last Updated: 09/26/2026